Altimmune Selloff On Clinical Hold A Buying Opportunity, Says JMP Securities

After speaking with management, JMP Securities analyst Jonathan Wolleben expects Altimmune to resolve the AdCOVID IND clinical hold in early January with Phase 1 data still expected in Q1.